Err modulators

WO2025096683A1PCT designated stage expired Publication Date: 2025-05-08UNIV OF HEALTH SCI & PHARMACY IN ST LOUIS
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/053752
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-10-30
Filing Date
2024-10-30
Publication Date
2025-05-08

AI Technical Summary

Technical Problem

There is a need for new compounds that can bind to estrogen receptor-related orphan receptors (ERR3) since these receptors lack well-characterized ligands, and existing technologies have not effectively addressed their modulation.

Method used

The development of compounds with specific chemical formulas that modulate the activity of ERR3, including phenyl, pyridine, thiophene, or naphthyl structures, with various substituents, which can interact with ERR3 to modulate their activity.

Benefits of technology

These compounds effectively modulate the activity of ERR3, potentially treating a wide range of diseases and disorders associated with these receptors, including diabetes, breast cancer, bone diseases, and metabolic disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000003_0001
    Figure IMGF000003_0001
  • Figure IMGF000004_0001
    Figure IMGF000004_0001
  • Figure IMGF000004_0002
    Figure IMGF000004_0002
Patent Text Reader

Abstract

In one aspect, the present disclosure describes compounds that may be used to modulate the activity of an estrogen receptor-related orphan receptor (EER). Also described are pharmaceutical formulations, methods of synthesis and uses thereof.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Estrogen receptor modulators

    US20040034081A9

  • Pyrazoline derivatives useful for the treatment of cancer

    US20070066651A1

  • Mitotic kinesin inhibitors and methods of use thereof

    US20170066733A1

  • 3, 5 -diphenyl- substituted pyrazolines for the treatment of cancer, proliferative, inflammatory or autoimmune diseases

    WO2012160447A1